A case of immune checkpoint inhibitor-associated myocarditis after chemotherapy for throat cancer
-
摘要: 本文报告1例接受免疫检查点抑制剂治疗的咽喉癌患者，诊断为免疫检查点抑制剂相关心肌炎。结合相关文献分析该病的病因、临床表现、辅助检查、治疗方法及转归，探讨免疫检查点抑制剂相关心肌炎的诊疗思路。Abstract: This article reports a case of throat cancer who was treated with immune checkpoint inhibitor and diagnosed with immune checkpoint inhibitor-associated myocarditis. The etiology, clinical symptoms, examinations, treatment methods, and outcomes of the disease were analyzed in combination with the relevant literature, and the diagnosis and treatment ideas of immune checkpoint inhibitor-associated myocarditis were discussed.
-
Key words:
- myocarditis /
- immune checkpoint inhibitor /
- throat cancer
-
-
图 7 免疫治疗相关性心肌炎识别和处理流程
Figure 7. Identification and treatment process of immunotherapy-related myocarditis
-
[1] Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges[J]. J Hematol Oncol, 2018, 11(1): 39. doi: 10.1186/s13045-018-0582-8
[2] Isazadeh A, Hajazimian S, Garshasbi H, et al. Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma[J]. J Cell Physiol, 2021, 236(2): 791-805. doi: 10.1002/jcp.29905
[3] Pirozzi F, Poto R, Aran L, et al. Cardiovascular toxicity of immune checkpoint inhibitors: clinical risk factors[J]. J Current Oncology Reports, 2021, 23: 13. doi: 10.1007/s11912-020-01002-w
[4] Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors[J]. Cardiovasc Res, 2019, 115(5): 854-868. doi: 10.1093/cvr/cvz026
[5] Lyon AR, Yousaf N, Battisti N, et al. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol, 2018, 19(9): e447-e458. doi: 10.1016/S1470-2045(18)30457-1
[6] 胡志全, 郭淳浩, 杨春光. 免疫检查点抑制剂治疗转移性去势抵抗性前列腺癌研究进展[J]. 临床泌尿外科杂志, 2022, 37(10): 729-734. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202210001.htm
[7] 王增增, 徐勇. 125 I粒子植入放疗对前列腺癌免疫微环境影响的初步分析[J]. 临床泌尿外科杂志, 2022, 37(4): 261-267. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202204004.htm
[8] Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC Review Topic of the Week[J]. J Am Coll Cardiol, 2019, 74(13): 1714-1727. doi: 10.1016/j.jacc.2019.07.079
[9] Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study[J]. Lancet Oncol, 2018, 19(12): 1579-1589. doi: 10.1016/S1470-2045(18)30608-9
[10] Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice[J]. Science, 2001, 291(5502): 319-322. doi: 10.1126/science.291.5502.319
[11] Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016, 375(18): 1749-1755. doi: 10.1056/NEJMoa1609214
[12] Zhang L, Jones-O'Connor M, Awadalla M, et al. Cardiotoxicity of immune checkpoint inhibitors[J]. Curr Treat Options Cardiovasc Med, 2019, 21(7): 32. doi: 10.1007/s11936-019-0731-6
[13] Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933.
[14] Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer[J]. Neurology, 2018, 91(10): e985-e994. doi: 10.1212/WNL.0000000000006124
[15] Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity[J]. Circulation, 2017, 136(21): 2085-2087. doi: 10.1161/CIRCULATIONAHA.117.030571
[16] Pudil R, Mueller C, Celutkiene J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology[J]. Eur J Heart Fail, 2020, 22(11): 1966-1983. doi: 10.1002/ejhf.2017
[17] Corrigendum to 'Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association(HFA), the European Association of Cardiovascular Imaging(EACVI)and the Cardio-Oncology Council of the European Society of Cardiology(ESC)'[J]. Eur J Heart Fail, 2021, 23(2): 345.
[18] Brahmer JR, Lacchetti C, Schneider BJ, et al. National comprehensive cancer, management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. doi: 10.1200/JCO.2017.77.6385
[19] 中国抗癌协会整合肿瘤心脏病学分会等. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47(20): 1027-1038. doi: 10.3969/j.issn.1000-8179.2020.20.148
-
下载:
图(8)
计量
- 文章访问数: 1204
- PDF下载数: 376
- 施引文献: 0